Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Congress 2021 Highlight videos

Learn about key study results presented during ESMO Congress 2021!

ESMO Highlight videos aim to cover results from a selection of important studies presented during the Congress.


Monday 20 September

Enriqueta Felip reports on LBA9 - IMpower010: patterns of relapse and subsequent therapy from a Phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in stage IB-IIIA non-small cell lung cancer (NSCLC)

Athanassios Argiris reports on LBA36 - CheckMate 651, a phase III trial of nivolumab/ipilimumab versus EXTREME regimen in first-line treatment of recurrent or metastatic SCCHN

Sunday 19 September

Jared Weiss reports on LBA6 - KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or in Combination With Cetuximab in Patients (Pts) With Colorectal Cancer (CRC) Harboring a KRASG12C Mutation

Susana Banerjee reports on 725MO - Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer (FRAME)

Gerhardt Attard reports on LBA4_PR - Abiraterone acetate and prednisolone (AAP) or AAP and enzalutamide (enza) added to androgen deprivation therapy (ADT) for men with high-risk locally advanced prostate cancer (PCa): metastases-free survival (MFS) results from STAMPEDE (NCT00268476)

Hope Rugo reports on LBA16 - Final results of KEYNOTE-355: A randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Thierry Conroy reports on LBA57 - Unicancer GI PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter randomized phase 3 trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas.

Saturday 18 September

Nicoletta Colombo reports on LBA2_PR - KEYNOTE-826: A randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer

Jason Luke reports on LBA3_PR - Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the Keynote 716 double-blinded phase III trial

Chiara Cremolini reports on LBA20 - FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO

Friday 17 September

Nicolas Girard reports on LBA66 - Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

Thomas Powles reports on LBA27 - Erdafitinib (ERDA) or ERDA Plus Cetrelimab (CET) for Patients With Metastatic or Locally Advanced Urothelial Carcinoma (mUC) and Fibroblast Growth Factor Receptor Alterations (FGFRa): First Phase 2 Results From the NORSE Study

Susana Banerjee reports on LBA32 - Principal results of the EORTC-1508 trial: A phase II randomised study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma

Eric Pujade-Lauraine reports on LBA33 - Retreatment with maintenance olaparib in patients (pts) with ovarian cancer (OC) previously treated with a PARP inhibitor (PARPi): randomized Phase IIIb OReO/ENGOT Ov-38 trial


This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.